Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2002 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,319,097

« Back to Dashboard

Summary for Patent: 5,319,097

Title: Pharmaceutical agents
Abstract:The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxy-carbonyl)amino-1-methylindol-3-yl-methyl]-3-methox ybenzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyll-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.
Inventor(s): Holohan; James J. (Macclesfield, GB2), Edwards; Ieuan J. (Congleton, GB2)
Assignee: Imperial Chemical Industries PLC (Millbank, GB2)
Application Number:07/805,421
Patent Claim Types:
see list of patent claims
Compound; Process; Formulation;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Patented / Exclusive Use
Astrazeneca
ACCOLATE
zafirlukast
Tablet; Oral020547-001SEP 26, 1996RXYes5,319,097<disabled>
Astrazeneca
ACCOLATE
zafirlukast
Tablet; Oral020547-003SEP 17, 1999RXNo5,319,097<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,319,097

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9027014Dec 12, 1990
United Kingdom9115107Jul 12, 1991

Non-Orange Book Patents for Patent: 5,319,097

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,993,859 Pharmaceutical agents<disabled in preview>
5,482,963 Pharmaceutical agents useful as leukotriene antagonists<disabled in preview>
5,612,367 Method of enhancing bioavailability of pharmaceutical agents<disabled in preview>
5,504,216 Method for reparing an amorphous sulfonamide<disabled in preview>
6,143,775 Process for preparing pharmaceutical composition containing a heterocyclic amide<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,319,097

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom2280606Feb 08, 1995
China1105705Apr 16, 2003
Australia656157Jan 27, 1995
China1062291Jul 01, 1992
Israel100091Aug 18, 1992
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc